Computational modeling of ovarian cancer dynamics suggests optimal strategies for therapy and screening
Published 2021 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Computational modeling of ovarian cancer dynamics suggests optimal strategies for therapy and screening
Authors
Keywords
-
Journal
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
Volume 118, Issue 25, Pages e2026663118
Publisher
Proceedings of the National Academy of Sciences
Online
2021-06-15
DOI
10.1073/pnas.2026663118
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Randomized phase III study to evaluate the impact of secondary cytoreductive surgery in recurrent ovarian cancer: Final analysis of AGO DESKTOP III/ENGOT-ov20.
- (2020) Andreas Du Bois et al. JOURNAL OF CLINICAL ONCOLOGY
- Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries
- (2018) Freddie Bray et al. CA-A CANCER JOURNAL FOR CLINICIANS
- Neoadjuvant chemotherapy versus debulking surgery in advanced tubo-ovarian cancers: pooled analysis of individual patient data from the EORTC 55971 and CHORUS trials
- (2018) Ignace Vergote et al. LANCET ONCOLOGY
- Optimal primary management of bulky stage IIIC ovarian, fallopian tube and peritoneal carcinoma: Are the only options complete gross resection at primary debulking surgery or neoadjuvant chemotherapy?
- (2017) Vasileios D. Sioulas et al. GYNECOLOGIC ONCOLOGY
- The prognostic value of perioperative, pre-systemic therapy CA125 levels in patients with high-grade serous ovarian cancer
- (2017) Taymaa May et al. INTERNATIONAL JOURNAL OF GYNECOLOGY & OBSTETRICS
- Lead time of rising CA-125 levels less than 35 u/mL predating radiologic confirmation of recurrent ovarian cancer.
- (2017) J. Bandyopadhyay et al. JOURNAL OF CLINICAL ONCOLOGY
- Neoadjuvant Chemotherapy Modulates the Immune Microenvironment in Metastases of Tubo-Ovarian High-Grade Serous Carcinoma
- (2016) S. Bo hm et al. CLINICAL CANCER RESEARCH
- Ovarian cancer screening and mortality in the UK Collaborative Trial of Ovarian Cancer Screening (UKCTOCS): a randomised controlled trial
- (2016) Ian J Jacobs et al. LANCET
- Inhibition of Spleen Tyrosine Kinase Potentiates Paclitaxel-Induced Cytotoxicity in Ovarian Cancer Cells by Stabilizing Microtubules
- (2015) Yu Yu et al. CANCER CELL
- Predictors of optimal cytoreduction in patients with newly diagnosed advanced-stage epithelial ovarian cancer: Time to incorporate laparoscopic assessment into the standard of care
- (2015) Natalia Rodriguez Gómez-Hidalgo et al. GYNECOLOGIC ONCOLOGY
- Primary chemotherapy versus primary surgery for newly diagnosed advanced ovarian cancer (CHORUS): an open-label, randomised, controlled, non-inferiority trial
- (2015) Sean Kehoe et al. LANCET
- Whole–genome characterization of chemoresistant ovarian cancer
- (2015) Ann-Marie Patch et al. NATURE
- Rise and fall of subclones from diagnosis to relapse in pediatric B-acute lymphoblastic leukaemia
- (2015) Xiaotu Ma et al. Nature Communications
- An apoptosis-enhancing drug overcomes platinum resistance in a tumour-initiating subpopulation of ovarian cancer
- (2015) D. M. Janzen et al. Nature Communications
- Immunotherapeutic approaches to ovarian cancer treatment
- (2015) Cariad Chester et al. Journal for ImmunoTherapy of Cancer
- Mathematical Modeling of PDGF-Driven Glioblastoma Reveals Optimized Radiation Dosing Schedules
- (2014) Kevin Leder et al. CELL
- The impacts of neoadjuvant chemotherapy and of debulking surgery on survival from advanced ovarian cancer
- (2014) Barry Rosen et al. GYNECOLOGIC ONCOLOGY
- Ovarian cancer
- (2014) Gordon C Jayson et al. LANCET
- Developing ovarian cancer stem cell models: laying the pipeline from discovery to clinical intervention
- (2014) Brendan Ffrench et al. Molecular Cancer
- Detection of Circulating Tumor DNA in Early- and Late-Stage Human Malignancies
- (2014) C. Bettegowda et al. Science Translational Medicine
- New developments in the treatment of ovarian cancer--future perspectives
- (2013) J. Lopez et al. ANNALS OF ONCOLOGY
- Evolution and Impact of Subclonal Mutations in Chronic Lymphocytic Leukemia
- (2013) Dan A. Landau et al. CELL
- The time interval from surgery to start of chemotherapy significantly impacts prognosis in patients with advanced serous ovarian carcinoma — Analysis of patient data in the prospective OVCAD study
- (2013) G. Hofstetter et al. GYNECOLOGIC ONCOLOGY
- Latest research and treatment of advanced-stage epithelial ovarian cancer
- (2013) Robert L. Coleman et al. Nature Reviews Clinical Oncology
- Evolutionary dynamics of cancer in response to targeted combination therapy
- (2013) Ivana Bozic et al. eLife
- Computational Modeling of Pancreatic Cancer Reveals Kinetics of Metastasis Suggesting Optimum Treatment Strategies
- (2012) Hiroshi Haeno et al. CELL
- Prognostic impact of the time interval between surgery and chemotherapy in advanced ovarian cancer: Analysis of prospective randomised phase III trials
- (2012) S. Mahner et al. EUROPEAN JOURNAL OF CANCER
- Whole-genome analysis informs breast cancer response to aromatase inhibition
- (2012) Matthew J. Ellis et al. NATURE
- The molecular evolution of acquired resistance to targeted EGFR blockade in colorectal cancers
- (2012) Luis A. Diaz Jr et al. NATURE
- Noninvasive Identification and Monitoring of Cancer Mutations by Targeted Deep Sequencing of Plasma DNA
- (2012) T. Forshew et al. Science Translational Medicine
- Dynamics of targeted cancer therapy
- (2012) Ivana Bozic et al. TRENDS IN MOLECULAR MEDICINE
- Primary Debulking Surgery Versus Neoadjuvant Chemotherapy in Stage IV Ovarian Cancer
- (2011) J. Alejandro Rauh-Hain et al. ANNALS OF SURGICAL ONCOLOGY
- An analysis of patients with bulky advanced stage ovarian, tubal, and peritoneal carcinoma treated with primary debulking surgery (PDS) during an identical time period as the randomized EORTC-NCIC trial of PDS vs neoadjuvant chemotherapy (NACT)
- (2011) Dennis S. Chi et al. GYNECOLOGIC ONCOLOGY
- Phenotypic heterogeneity and instability of human ovarian tumor-initiating cells
- (2011) J. M. Stewart et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Optimization of Dosing for EGFR-Mutant Non-Small Cell Lung Cancer with Evolutionary Cancer Modeling
- (2011) J. Chmielecki et al. Science Translational Medicine
- Early versus delayed treatment of relapsed ovarian cancer (MRC OV05/EORTC 55955): a randomised trial
- (2010) Gordon JS Rustin et al. LANCET
- Neoadjuvant Chemotherapy or Primary Surgery in Stage IIIC or IV Ovarian Cancer
- (2010) Ignace Vergote et al. NEW ENGLAND JOURNAL OF MEDICINE
- Adaptive Therapy
- (2009) R. A. Gatenby et al. CANCER RESEARCH
- Assessing Lead Time of Selected Ovarian Cancer Biomarkers: A Nested Case–Control Study
- (2009) Garnet L. Anderson et al. JNCI-Journal of the National Cancer Institute
- The evolution of tumor metastases during clonal expansion
- (2009) Hiroshi Haeno et al. JOURNAL OF THEORETICAL BIOLOGY
- Ovarian cancer
- (2009) Bryan T Hennessy et al. LANCET
Find Funding. Review Successful Grants.
Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.
ExploreBecome a Peeref-certified reviewer
The Peeref Institute provides free reviewer training that teaches the core competencies of the academic peer review process.
Get Started